Skip to main content
. 2009 Jan;20(1):68–77. doi: 10.1681/ASN.2008010036

Figure 1.

Figure 1.

Imatinib decreases cryoglobulin levels and serum Ig repertoire in TSLP-Tg mice. (A) The sera from vehicle-treated TSLP-Tg mice demonstrate visible cryoprecipitates but are dramatically reduced after 4 wk of treatment with imatinib. (B) Compared with vehicle-treated TSLP-Tg mice, a significant decrease of cryocrit is observed at each time point. Data are means ± SEM; n = 8 mice per group. Mann-Whitney test: *P < 0.05, **P < 0.01, ***P < 0.001: vehicle-treated TSLP-Tg mice versus imatinib-treated TSLP-Tg mice. (C) A significant decrease of serum Ig repertoire is seen after 4 wk of treatment with imatinib in TSLP-Tg mice. Data are means ± SEM; n = 6 to 8 mice per group. ANOVA, followed by Tukey-Kramer test: *P < 0.05, **P < 0.01, ***P < 0.001: vehicle-treated TSLP-Tg mice versus imatinib-treated TSLP-Tg mice; †P < 0.001: vehicle-treated WT mice versus vehicle-treated TSLP-Tg mice.